HIV DNA vaccine (PENNVAX-GP) - Inovio

Drug Profile

HIV DNA vaccine (PENNVAX-GP) - Inovio

Alternative Names: PENNVAX-GP; Pennvax-GP; PENNVAX-GP DNA vaccine - Inovio/NIAID; PENNVAX®-GP HIV immunotherapy

Latest Information Update: 07 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 24 May 2017 Efficacy data from a phase I trial in HIV infecctions released by Inovio
  • 30 Mar 2017 Inovio Pharmaceuticals plans a proof-of-concept clinical programme for HIV infections (Monotherapy, Combination therapy) in USA
  • 08 Aug 2016 National Institute of Allergy and Infectious Diseases completes enrolment in its phase I trial for HIV infections (In volunteers) in USA (NCT02431767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top